Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1711 to 1725 of 9024 results

  1. Ivacaftor–tezacaftor–elaxcaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in people 1 to under 2 years [TSID12295]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Noninvasive Vagus Nerve Stimulation For reactive airway disease

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Colli-pee void urine collection device (MT628) (MIB273)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  4. MT658 Quit Genius for Smoking Cessation

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  5. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation (MT512)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  6. Accuro handheld ultrasound device for locating intervertebral space for administration of spinal anaesthesia

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  7. PROPEL (mometasone furoate implant, 370ug) MT578 (MIB253)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  8. Acumen IQ sensor MT616 (MIB266)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  9. ABP-654 (ustekinumab biosimilar) for previously treated moderate to severe plaque psoriasis [TSID11790]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Ustekinumab for the treatment of moderately to severely active Crohn's disease in children [TS ID 11955]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Tarlatamab for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]

    In development Reference number: GID-TA11812 Expected publication date:  13 January 2027

    Technology appraisal guidance
    In development

  12. Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]

    In development Reference number: GID-TA11130 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Tucatinib with pertuzumab and trastuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]

    Awaiting development Reference number: GID-TA11487 Expected publication date:  27 May 2027

    Technology appraisal guidance
    Awaiting development

  14. Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]

    Awaiting development Reference number: GID-TA11626 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Omental lymph node transfer for lymphoedema of the limbs

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation